Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.
Ak MA, Sahip B, Geduk A, Ucar MA, Kale H, Hacibekiroglu T, Polat MG, Kalpakci Y, Bolaman AZ, Guvenc B, Ertop S. Ak MA, et al. Among authors: guvenc b. Indian J Hematol Blood Transfus. 2022 Apr;38(2):299-308. doi: 10.1007/s12288-021-01458-1. Epub 2021 Jun 26. Indian J Hematol Blood Transfus. 2022. PMID: 35496974 Free PMC article.
Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study.
Acar IH, Guner SI, Ak MA, Gocer M, Ozturk E, Atalay F, Sincan G, Yikilmaz AS, Ekinci O, Ince I, Gulturk E, Demir N, Dogan A, Ipek Y, Guvenc B. Acar IH, et al. Among authors: guvenc b. Mediterr J Hematol Infect Dis. 2022 Nov 1;14(1):e2022074. doi: 10.4084/MJHID.2022.074. eCollection 2022. Mediterr J Hematol Infect Dis. 2022. PMID: 36425152 Free PMC article.
Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data.
Aslaner Ak M, Gedük A, Acar İH, Polat MG, Sunu C, Bolaman AZ, Hacıbekiroğlu T, Güvenç B, Ertop Ş. Aslaner Ak M, et al. Among authors: guvenc b. Turk J Haematol. 2023 May 29;40(2):92-100. doi: 10.4274/tjh.galenos.2023.2022.0437. Epub 2023 Feb 17. Turk J Haematol. 2023. PMID: 36799095 Free PMC article.
Evaluation of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in Turkey: a multicenter retrospective analysis.
Karadag FK, Yenerel MN, Yılmaz M, Uskudar H, Ozkocaman V, Tuglular TF, Erdem F, Unal A, Ayyildiz O, Ozet G, Comert M, Kaya E, Ayer M, Salim O, Guvenc B, Ozdogu H, Mehtap Ö, Sonmez M, Guler N, Hacioglu S, Aydogdu İ, Bektas O, Toprak SK, Kaynar L, Yagci M, Aksu S, Tombak A, Karakus V, Yavasoglu İ, Onec B, Ozcan MA, Undar L, Ali R, Ilhan O, Saydam G, Sahin F. Karadag FK, et al. Among authors: guvenc b. Am J Blood Res. 2021 Jun 15;11(3):279-285. eCollection 2021. Am J Blood Res. 2021. PMID: 34322292 Free PMC article.
Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA, Ozet G, Koyuncu MB, Sonmez M, Akidan O, Ayli M, Yildirim M, Pehlivan M, Akkurd DM, Sahin H, Guvenc B, Okan V, Tiftik EN, Akdeniz A, Dincyurek HD, Gunes AK, Dagdas S, Acar HI, Ucar HK, Tombak A. Ucar MA, et al. Among authors: guvenc b. Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6557-6565. doi: 10.26355/eurrev_202111_27126. Eur Rev Med Pharmacol Sci. 2021. PMID: 34787859 Free article.
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey.
Soyer N, Ali R, Turgut M, Haznedaroğlu İC, Yılmaz F, Aydoğdu İ, Pir A, Karakuş V, Özgür G, Kiş C, Ceran F, İlhan G, Özkan M, Aslaner M, İnce İ, Yavaşoğlu İ, Gediz F, Sönmez M, Güvenç B, Özet G, Kaya E, Vural F, Şahin F, Töbü M, Durusoy R, Saydam G. Soyer N, et al. Among authors: guvenc b. Turk J Med Sci. 2021 Jun 28;51(3):1033-1042. doi: 10.3906/sag-1812-70. Turk J Med Sci. 2021. PMID: 33315343 Free PMC article.
90 results